02
What Is It?
A compounded product prepared by a pharmacy, typically as a lozenge dissolved under the tongue, combining sildenafil and tadalafil in one dose.
Product Profile & Review
COMPOUNDEDPRESCRIPTION
Compounded Sildenafil + Tadalafil Troche
Pharmacy-compounded dissolving tablets combining two PDE5 inhibitors. The ingredients are approved; the combination is not.
Also known as: Combination ED troche, Sublingual PDE5 combo
- Written by
- SynMale Editorial
- Originally Published
- October 2026
- Last Updated
- October 2026
- Medical Review
- Not yet independently reviewed
Executive Summary
- What is it?
- Compounded combination (sublingual troche) (Combination Product).
- What does it contain or claim to contain?
- Sildenafil (claimed), Tadalafil (claimed)
- How well verified is this specific product?
- Partially Verifiable
- Most important thing to know
- Two approved ingredients combined in a formulation that has not been studied as a combination.
C
Ingredient
Sildenafil + tadalafil
Product Type
Compounded combination (sublingual troche)
Regulatory Status
Compounded Medication
Verification
Partially Verifiable
03
Claimed Active Ingredients
- CLAIMED INGREDIENTSildenafilVaries by prescription
- CLAIMED INGREDIENTTadalafilVaries by prescription
A claimed ingredient is what a label or seller states. It is not treated as confirmed.
04
What Can We Verify?
Established
- Each ingredient is individually FDA-approved and well understood.
Uncertain or unverified
- The combination has not been evaluated in FDA-reviewed trials.
- Sublingual absorption claims are not well documented.
- Potency and consistency depend on the compounding pharmacy.
05
How It Works
The enzyme PDE5 normally breaks cGMP down. PDE5 inhibitors block that enzyme, so cGMP persists and smooth-muscle relaxation is sustained. They do not create arousal—stimulation is still required.
Combining a short-acting and a long-acting PDE5 inhibitor is proposed to give a fast start and long tail, but this has not been established in controlled trials.
06
Evidence Level
CLimited Evidence
Grades run from A (strong clinical evidence) to F (unsupported or contradicted). How we grade.
07
Clinical Profile
- Drug Class
- PDE5 Inhibitors (combination)
- Typical Onset
- Cannot be reliably established
- Effective Window
- Cannot be reliably established
- Half-Life
- Each component's own half-life applies
- Typical Medical Dosing
- Set by prescriber; not standardised
- Food Interaction
- Not established
- Alcohol Considerations
- Additive blood-pressure effects
- Daily vs On-Demand
- Usually on-demand
08
Benefits / Potential Advantages
- Allows custom dosing
- Alternative for people who have difficulty swallowing tablets
09
Limitations
- No FDA review of the combination
- Additive side effects from two drugs
- Variable quality between pharmacies
10
Side Effects & Precautions
Common effects
Those of both sildenafil and tadalafil, potentially additive.
Major interactions & warnings
- • Nitrates (e.g. nitroglycerin, isosorbide): combined use can cause a severe, potentially life-threatening drop in blood pressure. Contraindicated.
- • Riociguat and other guanylate cyclase stimulators: contraindicated for the same reason.
- • Alpha-blockers (e.g. doxazosin, tamsulosin): not universally contraindicated, but combined use can lower blood pressure and requires medical guidance on dosing and timing.
- • Significant cardiovascular disease: sexual activity itself carries cardiac load; a clinician should assess fitness before treatment.
- • Priapism: an erection lasting more than 4 hours is a medical emergency.
- • Sudden vision loss (rare NAION reports) or sudden hearing loss: stop use and seek urgent care.
11
Regulatory Status
FDA ApprovedFDA Cleared DeviceNot FDA ApprovedDietary SupplementCompounded MedicationForeign-Market MedicationUnknownUnverified
Compounded medications are prepared by licensed pharmacies for individual patients and are not FDA-approved. FDA does not verify their safety, effectiveness or quality before dispensing.
12
Marketing Claims vs. Evidence
Claim
What the Evidence Shows
“Faster under the tongue”
Plausible, but not established by robust comparative data.
“Best of both drugs”
The combination has not been shown to outperform either drug alone.
Risk & Verification Summary
Evidence Grade
C — Limited Evidence
Verification Level
Partially Verifiable
Regulatory Status
Compounded Medication
Risk Level
Moderate
No numerical performance score is shown because reliable performance data does not exist for this product.
SynMale Verdict
PLAUSIBLE
The pharmacology of each ingredient is solid, but the combination itself lacks controlled evidence and depends on pharmacy quality.
Bottom Line
What You Should Know
This product combines two approved drugs, but the combination has not been studied the way each drug has. Quality varies by pharmacy. Doubling up on PDE5 inhibitors can add up side effects. Discuss with a clinician whether a single approved medication would serve the same purpose.